Distribution of intranasal 11C-zolmitriptan assessed by positron emission tomography

Cephalalgia

Volumn 25, Issue 12, 2005, Pages 1103-1109

  Yates, R ^a   Sorensen J ^b   Bergström, Mats ^b,c   Antoni, G ^b   Nairn, K ^a   Kemp, J ^a   Langstrom B ^b   Dane, A ^a  

^a ASTRAZENECA   (United Kingdom)

^b UPPSALA UNIVERSITY   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Migraine treatment; Nasal administration; Positron emission tomography; Zolmitriptan

Indexed keywords

ZOLMITRIPTAN; CARBON; OXAZOLIDINONE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; SEROTONIN AGONIST; TRYPTAMINE DERIVATIVE;

ABDOMEN; ADULT; AEROSOL; ARTICLE; BRAIN LEVEL; BRAIN TISSUE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG TOLERABILITY; FEMALE; HUMAN; LUNG; MALE; NASOPHARYNX; NORMAL HUMAN; NOSE MUCOSA; POSITRON EMISSION TOMOGRAPHY; RADIOACTIVITY; ADOLESCENT; ANTIBODY SPECIFICITY; BRAIN; CLINICAL TRIAL; INHALATIONAL DRUG ADMINISTRATION; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; NOSE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RESPIRATORY TRACT MUCOSA; SCINTISCANNING; TISSUE DISTRIBUTION;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; BRAIN; CARBON RADIOISOTOPES; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; NASOPHARYNX; NOSE; ORGAN SPECIFICITY; OXAZOLIDINONES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RESPIRATORY MUCOSA; SEROTONIN AGONISTS; TISSUE DISTRIBUTION; TRYPTAMINES;

EID: 22244483918     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2005.00966.x     Document Type: Article

References (18)

1. 1B/1D receptor agonist for the acute oral treatment of migraine: a multicentre, dose-range finding study. Eur J Neurol 1998; 5:535-43.
2. Rapoport AM, Ramadan NM, Adelman JU, Mathew NT, Elkind AH, Kudrow DB, Earl NL. Optimizing the dose of zolmitriptan (Zornig™, 311C90) for the acute treatment of migraine. Neurology 1997; 49:1210-8.
3. Solomon GD, Cady RK, Klapper JA, Earl NL, Saper JR, Ramadan NM. On behalf of the 042 Clinical Trial Study Group. Clinical efficacy and tolerability of zolmitriptan for the acute treatment of migraine. Neurology 1997; 49:1219-25.
4. 1B/D agonist zolmitriptan (311C90): are brain stem sites therapeutic targets in migraine? Pain 1996; 67:355-9.
5. 1B/1D agonist for migraine. Cephalalgia 1997; 17 (Suppl. 18):4-14.
6. Yates R, Nairn K, Dixon R, Kemp JV, Dane AL. Preliminary studies of the pharmacokinetics and tolerability of zolmitriptan nasal spray in healthy volunteers. J Clin Pharmacol 2002; 42:1237-43.
7. Yates R, Nairn K, Dixon R, Kemp JV, Dane AL. Pharmacokinetics, dose proportionality, and tolerability of single and repeat doses of a nasal spray formulation of zolmitriptan in healthy volunteers. J Clin Pharmacol 2002; 42:1244-50.
8. 11C]-nicotine vapour in the human airway as visualized by positron emission tomography. Clin Pharmacol Ther 1995; 57:309-17.
9. Lunell E, Bergstrom M, Antoni G, Langstrom B, Nordberg A. Nicotine deposition and body distribution from a nicotine inhaler and a cigarette studied with positron emission tomography. Clin Pharm Ther 1996; 13:593-4.
10. 11C) Zanamivir following administration as an intranasal spray - evaluation with positron emission tomography. Clin Pharmacokinet 1999; 36 (Suppl. 1):33-9.
11. Langstrom B, Kihlberg T, Bergstrom M, Antoni G, Bjorkman M, Forngren BH et al. Compounds labelled with short-lived β+-emitting radionuclides and some applications in life sciences. The importance of time as a parameter. Acta Chem Scand 1999; 53:651-69.
12. Rota Kops E, Herzog H, Schmid A, Holte S, Feinendegen LE. Performance characteristics of an eight-ring whole body PET scanner. J Comput Assist Tomogr 1990; 14:437-45.
13. 1B/1D agonist zolmitriptan (311C90, Zomig™). Cephalalgia 1997; 17:849-54.
14. Hughes AM, Dixon R, Dane A, Kemp J, Cummings L, Yates RA. Effects of zolmitriptan (Zomig™) on central serotonergic neurotransmission as assessed by active oddball auditory event-related potentials in volunteers without migraine. Cephalalgia 1999; 19:100-6.
15. 1-like receptor agonists for a vascular aetiology. In: Sandler M, Collins GM, editors. Migraine: a spectrum of ideas. Oxford: Oxford University Press, 1990:147-72.
16. Humphrey PP, Feniuk W, Marriott AS, Tanner RJ, Jackson MR, Tucker ML. Pre-clinical studies on the antimigraine drug, sumatriptan. Eur J Neurol 1991; 31:282-90.
17. Gallagher RM, Dennish G, Spierings EL, Chitra R. A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine. Headache 2000; 40:119-28.
18. Geraud G, Olesen J, Pfaffenrath V, Tfelt-Hansen P, Zupping R, Diener HC, Sweet R for the Multinational Oral Zolmitriptan and Sumatriptan Comparative Study Group. Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design. Cephalalgia 2000; 20:30-8.